#None #TAG1 #NRG PALLAS #Radium-224

TAG1 and NRG PALLAS Expand Partnership

In a significant move that promises to improve the supply chain for medical isotopes, TAG1 Inc. has announced an expanded partnership with NRG PALLAS. This development follows the previous collaboration established in 2024 and focuses on producing Radium-224 for the production of Lead-212 (Pb-212) generators. This initiative is essential for accelerating the deployment of radiopharmaceuticals across Europe.

The Importance of Radium-224

Radium-224 serves as a crucial precursor for the production of Pb-212, which is pivotal for targeted alpha therapies (TATs) used in cancer treatment. The demand for localized isotope production has risen significantly, and this partnership aims to address those needs directly. By developing an efficient supply chain, TAG1 and NRG PALLAS are positioning themselves to meet the increasing requirements for decentralized isotope access, a key factor in the advancement of oncological treatments.

Expanding Clinical Access to Pb-212

"This partnership marks a significant step forward in TAG1's mission to expand clinical access to Pb-212," stated Sumit Verma, CEO and Founder of TAG1. The collaboration is set to enable the establishment of a regional supply of Radium-224, which will unlock new avenues for researchers and developers in radiopharmaceuticals throughout Europe. The goal is not only to increase production capacity but also to ensure that innovative therapies reach patients who can benefit from them the most.

Enhancing Radiopharmaceutical Innovation

NRG PALLAS, recognized as a leader in nuclear solutions and technology, plays a vital role in the validation and production processes of medical isotopes. Their ongoing project, which includes the construction of a new reactor, the PALLAS reactor, aims to secure a long-term and stable supply of isotopes necessary for both diagnostic and therapeutic purposes. By fortifying this partnership, both organizations are committing to meet the growing international demand for medical isotopes, which directly impacts patient treatment pathways.

The collaboration not only strengthens the supply infrastructure but also represents a forward-thinking approach to medical innovation in Europe. Maurits Wolleswinkel, CEO of NRG PALLAS, highlighted, "Making high-quality Radium-224 available is a key step in producing Lead-212 at scale and supporting the growth of targeted alpha therapy worldwide."

A Vision for the Future

As the need for effective cancer treatments continues to grow, ensuring a reliable supply of medical isotopes has never been more critical. This partnership stands to contribute significantly to that need, with both TAG1 and NRG PALLAS demonstrating a commitment to improving cancer care through groundbreaking radiopharmaceutical solutions.

In conclusion, this expanded collaboration between TAG1 and NRG PALLAS is a vital development for radiopharmaceutical supply and innovation. With the potential for enhanced patient access to essential treatments, it embodies a shared vision for the future of nuclear medicine in Europe and beyond.